论文部分内容阅读
目的:对冠心病合并高血脂患者给予阿托伐他汀联合常规疗法治疗,分析其临床疗效及对患者生存质量的影响。方法:选取2014年11月-2015年11月于台州市立医院治疗的冠心病合并高血脂患者112例,根据治疗方式不同将其分为观察组(n=56)与对照组(n=56)。给予对照组常规疗法治疗,给予观察组常规疗法的基础上外加阿托伐他汀治疗,对两组临床疗效、血脂水平变化、生活质量及不良反应进行比较。结果:在治疗总有效率方面,观察组89.3%与对照组62.5%比较显著提高(P<0.05);在血脂水平变化及生存质量评分方面,观察组与对照组治疗后血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平较治疗前均明显降低,高密度脂蛋白胆固醇(HDL-C)水平明显升高(P<0.05),与对照组比较,观察组上述指标改善程度更显著(P<0.05);在生存质量评分及6min步行距离方面,观察组与对照组治疗后生存质量评分明显降低,6min步行距离明显提高,比较差异具有显著性(P<0.05),与对照组比较,观察组生存质量评分及6min步行距离改善程度更显著(P<0.05)。在不良反应发生率方面,观察组与对照组比较差异无统计学意义(P<0.05)。结论:对冠心病合并高血脂患者给予常规疗法的基础上联合应用阿托伐他汀进行治疗能够显著提高临床疗效,明显改善血脂水平及生存质量,且不良反应较少,疗效安全有效,值得临床进一步推广应用。
OBJECTIVE: To treat patients with coronary heart disease complicated with hyperlipidemia by combination of atorvastatin and conventional therapy, and analyze its clinical effect and quality of life. Methods: A total of 112 patients with coronary heart disease complicated with hyperlipidemia who were treated in Taizhou Municipal Hospital from November 2014 to November 2015 were selected and divided into observation group (n = 56) and control group (n = 56) according to different treatment methods. . The patients in the control group were given routine therapy, and the patients in the observation group were treated with atorvastatin plus conventional therapy. The clinical efficacy, blood lipid levels, quality of life and adverse reactions were compared between the two groups. Results: The total effective rate of treatment group was significantly higher than that of control group (89.3% vs 62.5%, P <0.05); in terms of blood lipid level and quality of life score, TC, , Triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) were significantly lower than those before treatment and the level of HDL-C was significantly increased (P <0.05), compared with the control group (P0.05); in the quality of life score and 6-minute walking distance, the quality of life scores of the observation group and the control group were significantly decreased after treatment, the walking distance at 6min was significantly increased, the difference was significant (P < P <0.05). Compared with the control group, the quality of life in the observation group and the improvement degree of walking distance in 6min were more significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P <0.05). Conclusion: The treatment of coronary heart disease complicated with hyperlipidemia on the basis of conventional therapy combined with atorvastatin can significantly improve the clinical efficacy, significantly improve blood lipid levels and quality of life, and fewer adverse reactions, the efficacy of safe and effective, it is worth further clinical Promote the application.